Clinical trialNCT03423628Active, not recruitingPhase 1Interventional

A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer

SponsorAstraZenecaEnrollment159Brain Neoplasms, MalignantLeptomeningeal Disease (LMD)Primary Glioblastoma MultiformeRecurrent Glioblastoma Multiforme

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study will test an investigational drug called AZD1390 in combination with radiation therapy for the treatment of brain tumors. This is the first time AZD1390 is being given to patients. This study will test safety, tolerability and PK (how the drug is absorbed, distributed and eliminated) of ascending doses of AZD1390 in combination with distinct regimens of radiation therapy

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Anthony Chalmers
Beatson West of Scotland Cancer Centre
Principal Investigator
clinicaltrials.gov ↗
Brandon Imber
Memorial Sloan Kettering Cancer Center
Principal Investigator
clinicaltrials.gov ↗
Deborah Forst
Massachusetts General Hospital
Principal Investigator
clinicaltrials.gov ↗
Jan Drappatz
UPMC Hospital Radiation Oncology
Principal Investigator
clinicaltrials.gov ↗
Kazuhiko Mishima
Saitama Medical University International Medical Center
Principal Investigator
clinicaltrials.gov ↗
Louise Murray
University of Leeds
Principal Investigator
clinicaltrials.gov ↗
Mariza Daras
VCU Massey Cancer Center
Principal Investigator
clinicaltrials.gov ↗
Patrick Wen
Dana-Farber Cancer Institute
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗
Rajesh Jena
Cambridge University Hospitals NHS Foundation Trust
Principal Investigator
clinicaltrials.gov ↗
Yoshiki Arakawa
Kyoto University Hospital
Principal Investigator
clinicaltrials.gov ↗
Yoshitaka Narita
National Cancer Center Hospital
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

11 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Japan

Research Site
Chūōku, Japan
Research Site
Hidaka-shi, Japan
Research Site
Kyoto, Japan

United Kingdom

Research Site
Cambridge, United Kingdom
Research Site
Glasgow, United Kingdom
Research Site
Leeds, United Kingdom

United States

Research Site
Boston, Massachusetts, United States
Research Site
Boston, Massachusetts, United States
Research Site
New York, New York, United States
Research Site
Pittsburgh, Pennsylvania, United States
Research Site
Richmond, Virginia, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Azd-1390

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 2 Apr 2018
Primary completion: 3 Sept 2026
Completion: 3 Sept 2026
Last update posted: 17 Jul 2026
Registered enrollment: 159
Registry id: NCT03423628

Cross-registrations

EU-CTR / CTIS (EudraCT)2017-002451-28

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.